Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC

International Immunopharmacology

Volumn 28, Issue 1, 2015, Pages 208-214

  Jiang, Pan ^a   Zhang, Yan ^a   J Archibald, Steve ^b   Wang, Hua ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF HULL   (United Kingdom)

^c Guangzhou Yidai Pharmaceutical Co Ltd   (China)

Author keywords

Adoptive cell transfer; Chemotherapy; Head and neck squamous cell carcinoma

Indexed keywords

BLEOMYCIN A5; CD3 ANTIGEN; CD4 ANTIGEN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 2; OKT 3; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CELL CULTURE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LYMPHOCYTE PROLIFERATION; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADICAL RESECTION; RETROSPECTIVE STUDY; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; AGED; CARCINOMA, SQUAMOUS CELL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHEMISTRY; DISEASE FREE SURVIVAL; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MONOCYTE; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NECK DISSECTION; NEOADJUVANT THERAPY; PROCEDURES; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONOCYTES; NECK DISSECTION; NEOADJUVANT THERAPY; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; SURVIVAL; YOUNG ADULT;

EID: 84935860270     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.05.042     Document Type: Article

References (33)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics 2013 11 30
2. M.P. Colombo, and S. Piconese Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy Nat. Rev. Cancer 7 2007 880 887
3. D.R. Green, T. Ferguson, L. Zitvogel, and G. Kroemer Immunogenic and tolerogenic cell death Nat. Rev. Immunol. 9 2009 353 363
4. I.G. Schmidt-Wolf, P. Lefterova, B.A. Mehta, L.P. Fernandez, D. Huhn, and K.G. Blume Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells Exp. Hematol. 21 1993 1673 1679
5. R.G. van der Most, A.J. Currie, B.W. Robinson, and R.A. Lake Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all Cell Death Differ. 15 2008 13 20
6. R. Li, C. Wang, L. Liu, C. Du, S. Cao, and J. Yu Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study Cancer Immunol. Immunother. 61 2012 2125 2133
7. D. Bernardi, I. Milan, M. Balzarotti, M. Spina, A. Santoro, and U. Tirelli Comprehensive geriatric evaluation in elderly patients with lymphoma: feasibility of a patient-tailored treatment plan J. Clin. Oncol. 21 2003 754 755
8. B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, and R. Bouabdallah CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N. Engl. J. Med. 346 2002 235 242
9. X. Poire, J. Kline, D. Grinblatt, T. Zimmerman, K. Conner, and C. Muhs Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas Leuk. Lymphoma 51 2010 1241 1250
10. Y. Zhu, H. Zhang, Y. Li, J. Bai, L. Liu, and Y. Liu Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer Cancer Immunol. Immunother. 62 2013 1629 1635
11. R. Ramakrishnan, D. Assudani, S. Nagaraj, T. Hunter, H.I. Cho, and S. Antonia Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice J. Clin. Investig. 120 2010 1111 1124
12. M.J. Chung, J.Y. Park, S. Bang, S.W. Park, and S.Y. Song Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer Cancer Immunol. Immunother. 63 2014 939 946
13. M. Nishino, D.M. Jackman, H. Hatabu, B.Y. Yeap, L.A. Cioffredi, and J.T. Yap New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy Am. J. Roentgenol. 195 2010 W221 W228
14. C.R. Leemans, B.J. Braakhuis, and R.H. Brakenhoff The molecular biology of head and neck cancer Nat. Rev. Cancer 11 2011 9 22
15. D.H. Kang, M.T. Weaver, N.J. Park, B. Smith, T. McArdle, and J. Carpenter Significant impairment in immune recovery after cancer treatment Nurs. Res. 58 2009 105 114
16. J.P. Pignon, J. Bourhis, C. Domenge, and L. Designe Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer Lancet 355 2000 949 955
17. V. Bronte, and S. Mocellin Suppressive influences in the immune response to cancer J. Immunother. 32 2009 1 11
18. J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, and A. Chevriaux 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res. 70 2010 3052 3061
19. P. Olioso, R. Giancola, M. Di Riti, A. Contento, P. Accorsi, and A. Iacone Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial Hematol. Oncol. 27 2009 130 139
20. R.A. Lake, and B.W. Robinson Immunotherapy and chemotherapy - a practical partnership Nat. Rev. Cancer 5 2005 397 405
21. S. Thanendrarajan, M. Nowak, H. Abken, and I.G. Schmidt-Wolf Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk. Res. 35 2011 1136 1142
22. B. Yang, X.C. Lu, R.L. Yu, X.H. Chi, Y. Liu, and Y. Wang Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial Hematol. Oncol. 30 2012 115 122
23. J. Jiang, N. Xu, C. Wu, H. Deng, M. Lu, and M. Li Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells Anticancer Res. 26 2006 2237 2242
24. R. Ramakrishnan, S. Antonia, and D.I. Gabrilovich Combined modality immunotherapy and chemotherapy: a new perspective Cancer Immunol. Immunother. 57 2008 1523 1529
25. W. Wang, P. Hodkinson, F. McLaren, A. MacKinnon, W. Wallace, and S. Howie Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3 + cells in tumour infiltrate Int. J. Cancer 131 2012 E928 E937
26. M. Shi, B. Zhang, Z.R. Tang, Z.Y. Lei, H.F. Wang, and Y.Y. Feng Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma World J. Gastroenterol. 10 2004 1146 1151
27. Q. Niu, W. Wang, Y. Li, S. Qin, Y. Wang, and G. Wan Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies Int. Immunopharmacol. 11 2011 449 456
28. L. Yang, B. Ren, H. Li, J. Yu, S. Cao, and X. Hao Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients Cancer Immunol. Immunother. 62 2013 65 73
29. M.S. Nars, and R. Kaneno Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy Int. J. Cancer 132 2013 2471 2478
30. K. Yamasaki, S. Horiguchi, M. Kurosaki, N. Kunii, K. Nagato, and H. Hanaoka Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy Clin. Immunol. 138 2011 255 265
31. H. Li, J.P. Yu, S. Cao, F. Wei, P. Zhang, and X.M. An CD4 + CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients J. Clin. Immunol. 27 2007 317 326
32. C. Wu, J. Jiang, L. Shi, and N. Xu Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer Anticancer Res. 28 2008 3997 4002
33. H. van Meir, G.G. Kenter, J. Burggraaf, J.R. Kroep, M.J. Welters, and C.J. Melief The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy Anticancer Agents Med Chem. 14 2014 190 203